Locametz is owned by Aaa Usa Novartis.
Locametz contains Gallium Ga-68 Gozetotide.
Locametz has a total of 1 drug patent out of which 0 drug patents have expired.
Locametz was authorised for market use on 23 March, 2022.
Locametz is available in powder;intravenous dosage forms.
Locametz can be used as for use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer.
The generics of Locametz are possible to be released after 15 August, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US11369590||AAA USA NOVARTIS||PSMA binding ligand-linker conjugates and methods for using|| |
(5 years from now)
|New Product (NP)||Mar 23, 2025|
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 23 March, 2022
Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic